Drug Trial Radar · NCT07647107
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
Jul 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- PT Bio FarmaIndustry
- Sponsor type
- Industry
- Collaborators
- Fakultas Kedokteran Universitas Indonesia; Dr Cipto Mangunkusumo General Hospital
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia
Conditions
- Tuberculosis
- TB Infection
Interventions
LipovaxinS4-EAH (Middle Dose)Biological
0,5 mL of Middle Dose LipovaxinS4-EAH. Administered twice, 28 days apart
LipovaksinS4-EAH (High Dose)Biological
0,5 mL of HIgh Dose LipovaxinS4-EAH. Administered twice, 28 days apart
PlaceboBiological
0,5 mL of Placebo containing NaCl 0.9%. Administered twice, 28 days apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Local and systemic reactionsTime frame: 30 minutes, 7 days and 28 days after 1st injection and 2nd injection for all group, and 30 minutes, 7 days and 28 days after 1st injection and 2nd injection and 14 days after 1st dose for sentinel group
- Any AEs and SAEsTime frame: until 6 months after 2nd injection
- Laboratory changesTime frame: D0, 14 days after 1st injection (sentinel), 28 days after 2nd injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.
Jakarta Pusat, DKI Jakarta, Indonesia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.